Nascent Biotech Inc. (NBIO)
Stock Price: $0.0625 USD
0.0020 (2.46%)
Updated Jan 13, 2021 3:57 PM EST - Market closed
| Market Cap | 4.80M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.02M |
| Shares Out | 64.34M |
| EPS (ttm) | -0.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 13 |
| Last Price | $0.0625 |
| Previous Close | $0.0610 |
| Change ($) | 0.0020 |
| Change (%) | 2.46% |
| Day's Open | 0.0617 |
| Day's Range | 0.0591 - 0.0645 |
| Day's Volume | 67,592 |
| 52-Week Range | 0.0437 - 0.35 |
News
There are no news available yet.
About NBIO
Nascent Biotech, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as lung and breast cancer metastases to the brain; and pancreatic cancer. The company has a research collaboration agreement with Manhattan BioSolutions, Inc. to initiate a vaccine program for the prevention of COVID-19 or other viral infections; and a co... [Read more...]
| Industry Biotechnology | |
| CEO Sean Carrick | |
| Stock Exchange OTCMKTS | Ticker Symbol NBIO |